ERBB2 and metastatic neoplasm: Vyloy (zolbetuximab-clzb) is FDA approved to treat CLDN18.2-positive, HER2-negative EGJ adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy for locally advanced unresectable or metastatic disease [160].